Transitional cell carcinoma of the urethra is a rare cancer that begins in the cells lining the urethra, the tube that carries urine out of the body. Treatment depends on the stage and location of the tumor, and may involve surgery, chemotherapy, or radiation therapy. Because this cancer is uncommon, most treatment approaches are based on decades of clinical experience rather than large studies.

Understanding Treatment Goals for Urethral Cancer

When someone receives a diagnosis of transitional cell carcinoma of the urethra, the treatment plan becomes highly individualized. The main goals focus on removing or destroying cancer cells, preventing the disease from spreading to other parts of the body, and maintaining quality of life as much as possible. Treatment success depends heavily on how early the cancer is caught and where exactly it’s located in the urethra.^[1]

Doctors consider many factors when planning treatment. The size of the tumor matters, as does whether it has grown deeper into tissues or spread to nearby lymph nodes. In males, the urethra runs about 8 inches through the prostate and penis, while in females it’s only about 2 inches long and sits just above the vagina. This anatomical difference affects both how the cancer behaves and which treatment options work best.^[10][13]

Transitional cell carcinoma gets its name from the special cells that line the urethra, called transitional cells or urothelial cells. These cells have a unique ability to stretch and change shape, allowing the urinary tract to expand when holding urine and contract when empty. When these cells become cancerous, they can form tumors anywhere along the urethral lining.^[1][4]

Because urethral cancer is so rare, with only about 1,615 cases reported in the United States between 1973 and 2002, treatment recommendations come mainly from medical societies drawing on decades of accumulated experience from major academic centers. Standard treatments have been established through years of clinical practice, while researchers continue exploring new approaches through clinical trials to find better ways to help patients.^[10]

Standard Treatment Approaches

The primary treatment for transitional cell carcinoma of the urethra typically involves surgery. The type of surgical procedure depends on where the tumor is located and how deeply it has invaded surrounding tissues. For tumors in the distal urethra (the part nearest the opening), doctors may perform a more limited surgery. For proximal tumors (deeper inside, closer to the bladder), more extensive surgery may be necessary.^[10]

In males with cancer in the distal or pendulous urethra, surgeons might remove just that section. However, when cancer affects the proximal or bulbomembranous urethra, treatment often requires removing the bladder, prostate, and urethra together in a procedure that significantly impacts quality of life. In females, distal urethral tumors may be treated with partial removal of the urethra, while proximal tumors might require removal of the urethra, bladder, and sometimes parts of the vaginal wall.^[10]

Radiation therapy uses high-energy beams to kill cancer cells or stop them from growing. This treatment can be given alone or combined with surgery. Some patients receive radiation before surgery to shrink tumors, making them easier to remove. Others receive it after surgery to eliminate any remaining cancer cells. Radiation can also serve as the main treatment for patients who cannot undergo surgery due to other health conditions.^[4]

Chemotherapy involves using drugs to destroy cancer cells throughout the body. For urethral cancer, chemotherapy may be given before surgery to shrink tumors, after surgery to eliminate remaining cells, or as the primary treatment when cancer has spread beyond the urethra. Because transitional cell carcinoma of the urethra comes from the same type of cells that line the bladder, doctors often use similar chemotherapy drugs as those proven effective for bladder cancer.^[8][12]

The duration of treatment varies widely. Surgery typically happens in a single procedure, though recovery can take weeks or months depending on the extent of the operation. Radiation therapy usually involves daily sessions over several weeks. Chemotherapy regimens may continue for several months, with treatment cycles alternating with rest periods to allow the body to recover from side effects.

Side effects from treatment can be substantial. Surgery may cause pain, infection, and changes in urinary function. Some patients require permanent alterations in how they urinate, such as a urostomy (an opening in the abdomen for urine to drain into a collection bag). Radiation therapy can cause skin irritation, fatigue, and inflammation of urinary tract tissues. Chemotherapy side effects often include nausea, hair loss, fatigue, increased infection risk due to low blood cell counts, and nerve damage causing numbness or tingling in hands and feet.^[4]

Innovative Treatments in Clinical Trials

Clinical trials represent the frontier of cancer treatment, where researchers test new therapies to determine if they work better than standard treatments or offer hope when standard treatments haven’t worked. For transitional cell carcinoma, several promising approaches are being investigated, though specific trial information for urethral cancer is limited due to its rarity.

Because transitional cell carcinoma of the urethra shares cellular characteristics with bladder cancer, many innovative treatments being studied for bladder cancer may eventually prove useful for urethral cancer as well. Immunotherapy has emerged as a particularly exciting area of research. These treatments work by helping the patient’s own immune system recognize and attack cancer cells more effectively.^[8][12]

One type of immunotherapy uses checkpoint inhibitors, drugs that remove the “brakes” cancer cells put on the immune system. In bladder cancer trials, drugs that target proteins called PD-1 or PD-L1 have shown promise, particularly for patients whose cancer has advanced or returned after initial treatment. These medications work by blocking signals that cancer cells use to hide from immune system attack.^[12]

Targeted therapy represents another innovative approach. These treatments focus on specific molecules or pathways that cancer cells need to grow and survive. Researchers identify particular genetic changes or protein patterns in tumors, then develop drugs that specifically interfere with those targets while causing less damage to normal cells than traditional chemotherapy.^[8]

Clinical trials progress through distinct phases. Phase I trials focus primarily on safety, testing new treatments in small groups of patients to determine appropriate doses and identify side effects. Phase II trials expand to larger groups to evaluate whether the treatment actually works against cancer while continuing to monitor safety. Phase III trials compare new treatments directly against current standard treatments in large patient populations to determine which approach works better.

Participation in clinical trials happens at various locations, including major academic medical centers in the United States, Europe, and other regions. However, because urethral cancer is so rare, specific trials focusing exclusively on this cancer type are uncommon. Patients may instead be eligible for trials studying treatments for transitional cell carcinomas more broadly, including bladder cancer trials that accept patients with other urothelial cancers.

Trial eligibility depends on many factors: the stage and type of cancer, previous treatments received, overall health status, and specific characteristics of the tumor. Patients interested in clinical trials should discuss options with their oncology team, who can search trial databases and determine if any appropriate studies are enrolling patients.

Combination Approaches and Treatment Decisions

Many patients receive combination treatments rather than a single approach. For example, someone might undergo chemotherapy first to shrink a tumor, followed by surgery to remove it, then radiation therapy to eliminate any remaining cancer cells. This multimodal approach aims to attack cancer from multiple angles, potentially improving outcomes.^[4]

Treatment decisions require balancing cancer control against quality of life. More aggressive treatments may offer better chances of eliminating cancer but come with more severe side effects and lifestyle changes. Less aggressive approaches may preserve more normal function but might not control cancer as effectively. These trade-offs vary enormously from person to person based on age, overall health, personal values, and specific cancer characteristics.

The location of the tumor particularly influences treatment choices. Distal urethral tumors, occurring near the urethral opening, tend to be diagnosed earlier and generally have better outcomes with less extensive surgery. Proximal tumors, located deeper and closer to the bladder, often require more aggressive surgery and have more challenging prognoses because they’re typically more advanced when discovered.^[10]

Most common treatment methods

• Surgery
  • Removal of the affected portion of the urethra for localized disease
  • More extensive surgery involving bladder, prostate (in males), or vaginal wall (in females) for advanced tumors
  • Surgical approach depends on tumor location (distal versus proximal urethra)
  • May require creation of alternative urinary drainage systems
• Radiation Therapy
  • Can be used alone or combined with surgery
  • May be given before surgery to shrink tumors
  • Often administered after surgery to eliminate remaining cancer cells
  • Serves as primary treatment for patients unable to undergo surgery
  • Typically involves daily sessions over several weeks
• Chemotherapy
  • Uses drugs similar to those effective for bladder cancer due to shared cell origin
  • May be given before surgery (neoadjuvant), after surgery (adjuvant), or as primary treatment for metastatic disease
  • Treatment cycles alternate with rest periods over several months
  • Works throughout the body to eliminate cancer cells
• Immunotherapy
  • Checkpoint inhibitors that help the immune system attack cancer cells
  • Drugs targeting PD-1 or PD-L1 proteins show promise in related bladder cancers
  • Being investigated in clinical trials for transitional cell carcinomas
  • May offer options when standard treatments haven’t worked
• Targeted Therapy
  • Focus on specific molecules or pathways cancer cells need to survive
  • Aim to cause less damage to normal cells than traditional chemotherapy
  • Under investigation in clinical trials for urothelial cancers
  • Require identification of specific genetic changes or protein patterns in tumors